REFERENCES

1. Paterson DL. The epidemiological profile of infections with multidrug-resistant pseudomonas aeruginosa and acinetobacter species. ClinInfec Dis. 2006; 43:S43–8. [PubMed]
2. Bergogne-Bérézin E, Towner JK. Acinetobacter spp. as nosocomial pathogens: Microbiological, clinical and epidemiological features. ClinMicrobiol Rev. 1996; 9:148–51. [PMC free article] [PubMed]
3. Koneman WE, Allen DS, Dowell VR, Jr, Sommers MH. Colour Atlas and Text Book of Diagnostic Microbiology. 2nd ed. Philadelphia/St. Louis/London: J. B. Lippincott Company; 1983. The nonfermentative Gram negative bacilli; pp. 125–84.
4. Anstey NM, Currie BJ, Withnall KM. Community-acquired Acinetobacter pneumonia in the northern territory of Australia. Clin Infect Dis. 1992; 14:83–91. [PubMed]
5. Goodhart GL, Abrutyn E, Watson R, Root RK, Egert J. Communityacquired Acinetobactercalcoaceticusvar anit atus pneumonia. JAMA. 1977; 238:1516–8. [PubMed]
6. Anstey NM, Currie BJ, Hassell M, Palmer D, Dwyer B, Seifert H. Community-acquired bacteremic Acinetobacter pneumonia in tropical Australia is caused by diverse strains of Acinetobacterbaumannii, with carriage in the throat of at-risk groups. J ClinMicrobiol. 2002; 40:685–6. [PMC free article] [PubMed]
7. Chen MZ, Hsueh PR, Lee LN, Yu CJ, Yang PC, Luh KT. Severe community-acquired pneumonia due toAcinetobacterbaumannii. Chest. 2001; 120:1072–7. [PubMed]
8. Neely AN, Maley MP, Warden GD. Computer keyboards as reservoirs for Acinetobacterbaumannii in a burn hospital. Clin Infect Dis. 1999; 29:1358–60. [PubMed]
9. Glew RH, Moellering RC, Jr, Kunz LJ. Infections with Acinetobactercalcoaceticus (Herelleavaginicola): Clinical and laboratory studies. Medicine (Baltimore) 1977; 56:79–97. [PubMed]
10. Paramasivan CN, Rao RS, Sivadasan K, Anupurba S, Kanungo R, Prabhekar R. Non-fermenting Gram negative bacteria in human infections. Indian J Med Microbiol. 1988; 6:73–9.
11. Seifert H, Baginski R, Schulze A, Pulverer G. Antimicrobial susceptibility of Acinetobacter species.Antimicrob Agents Chemother. 1993; 37:750–3. [PMC free article] [PubMed]
12. Fuchs PC, Barry AL, Brown SD. In vitro activities of ertapenem (MK-0826) against clinical isolates from eleven North American medical centers. Antimicrob Agents Chemother. 2001;45:1915–8.[PMC free article] [PubMed]
13. Abbo A, Venezia SN, Muntz ZH, Krichali T, Igra YS, Carmeli Y. Multidrug-resistant Acinetobacterbaumannii. Emerg Infect Dis. 2005 Jan; 11(1):22-9.
14. Manchanda V, Sanchaita S, Singh NP. Multidrug resistant Acinetobacter. J Glob Infect Dis. 2010 Sep; 2(3):291-304.
15. Rosenbaum P, Aureden K, Cloughessy M, Goss L, Kassai M, Streed SA. Guide to the elimination of multidrugresistantAcinetobacterbaumanniitransmission in Healthcare Settings. Washington, DC: Association for Professionals in Infection Control and Epidemiology; 2010.
16. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: 20th informational supplement. CLSI document M100-S20. Wayne, Pennsylvania: Clinical and Laboratory Standards Institute; 2010.
17. Bergogue–Berezin E, Towner KJ. Acinetobacter species as nosocomial pathogen: Microbiological, clinical and epidemiological features. ClinMicrobiol Rev. 1996; 9:148–65. [PMC free article] [PubMed]

 

STATPERSON PUBLISHING GROUP | Aurangabad | Maharashtra |2016 | INDIA
© Copyright 2016 Statperson Publishing Corporation. a division of Statperson Consultancy.
All Rights Reserve